Communiqués Hansa Biopharma AB Mexican S.E.

Actions

HNSA N

SE0002148817

Cours en clôture Mexican S.E. Autres places de cotation 00:00:00 16/03/2023			Varia. 5j.	Varia. 1 janv.
160,8 ^MXN	-.--%		-.--%	-.--%

27/06	Hansa Biopharma AB (publ) annonce des nominations au conseil d'administration	CI
31/05	Hansa Biopharma finalise la randomisation des patients pour l'utilisation de l'Imlifidase dans un essai de transplantation rénale	MT

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

Hansa Biopharma: increase in number of shares and votes	07:01	AQ
Bulletin from the Annual General Meeting in Hansa Biopharma AB (publ)	27/06	AQ
Hansa Biopharma publishes prospectus for admission to trading of shares on Nasdaq Stockholm	07/06	AQ
Hansa Biopharma Completes Randomization in Pivotal Phase 3 US ConfIdeS Trial	31/05	AQ
Notice to Annual General Meeting in Hansa Biopharma AB (publ)	27/05	AQ
Hansa Biopharma to present data at 2024 American Transplant Congress annual meeting	21/05	AQ
Correction, Hansa Biopharma, increase in number of shares and votes	06/05	AQ
Correction: Hansa Biopharma: increase in number of shares and votes	03/05	PU
Hansa Biopharma: increase in number of shares and votes	03/05	AQ
Hansa Biopharma Q1 - Improved European launch support	19/04	AQ
Hansa Biopharma interim report January-March 2024	18/04	AQ
Hansa Biopharma Announces Successful Execution of a Directed Share Issue of SEK 372 million (~USD 34.6 million)	12/04	AQ
Hansa Biopharma Expects Strong First Quarter 2024 Sales Performance	02/04	AQ
Hansa Biopharma publishes 2023 Annual and Sustainability Reports	21/03	AQ
Evan Ballantyne to join Hansa Biopharma as Chief Financial Officer	22/02	AQ
Hansa Biopharma - Improved sales prospects	05/02	AQ
Hansa Biopharma Year-end report January-December 2023	02/02	AQ
Hansa Biopharma provides update on business and key financials ahead of the JP Morgan Healthcare Conference	06/01	AQ
Hansa Biopharma - Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation	15/12	AQ
Imlifidase met primary endpoint in 16-HMedIdes-12 phase 2 trial in patients with AMR following kidney transplantation	14/12	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués Hansa Biopharma AB Mexican S.E.

Actions

HNSA N

SE0002148817

Communiqués

Filtres